Detail of "108-40-7"

Reference

Methyl substituted thioxanthones and thioxanthone-10,10-dioxides

Methyl substituted thioxanthones and thioxanthone-10,10-dioxides. Brindle, Ian D.Several substances are used for example 87548-97-8 and 108-40-7 which are their cas registry numbers.; Doyle, Paul P. (Dep. Chem., Brock Univ., St. Catharines, ON L2S 3A1, Can.). Can. J. Chem., 61(8), 1869-71 (English) 1983. CODEN: CJCHAG. ISSN: 0008-4042. DOCUMENT TYPE: Journal CA Section: 27 (Heterocyclic Compounds (One Hetero Atom)) All four monomethylthioxanthones (I) and their corresponding dioxides were prepd. A previously published synthesis of the 2- and 3-methylthioxanthones by H. Gilman et al (1959) has been shown to produce the 2- and 4-Me isomers. .

Preparation of immunosuppressant heterocyclic compounds for treating or preventing diseases associated with EDG receptor mediated signal transduction

Preparation of immunosuppressant heterocyclic compounds for treating or preventing diseases associated with EDG receptor mediated signal transduction. Mi, Yuan; Pan, Shifeng; Gray, Nathanael S.; Gao, Wenqi; Fan, Yi; Jiang, Tao (IRM, LLC, Bermuda). PCT Int. Appl. WO 2005000833 A1 6 Jan 2005, 71 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). (World Intellectual Property Organization). CODEN: PIXXD2. CLASS: ICM: C07D333-60. APPLICATION: WO 2004-US15702 19 May 2004. PRIORITY: US 2003-2003/PV47193U 19 May 2003; US 2004-2004/PV562183 14 Apr 2004. DOCUMENT TYPE: Patent CA Section: 28 (Heterocyclic Compounds (More Than One Hetero Atom)) Section cross-reference(s): 1, 63 The present invention relates to immunosuppressant I [n = 1-2; A = C(O)OR9, OP(O)(OR9)2, P(O)(OR9)2, SO2OR9, P(O)(R9)OR9, 1H-tetrazol-5-yl (wherein R9 = H, alkyl); X = a bond, alkylene, heteroarylene, etc.; Y = (un)substituted fused 5,6 or 6,6 hetero bicyclic system consisting of at least one arom. ring; R1 = (un)substituted (hetero)aryl; R2-R3, R5-R8 = H, alkyl, halo, OH, etc.; R4 = H, alkyl; or R7 and either R2, R4 or R5 together with the atoms to which R2, R4, R5 and R7 are attached forms satd. or partially unsatd. 4-7 membered ring], process for their prodn., their uses and pharmaceutical compns. contg. them. E. 108-40-7 and 820240-99-1 are also in the experiment.g., a multi-step synthesis of II, starting from 5-methylbenzo[b]thiophene, was given. The compds. I are useful in the treatment or prevention of diseases or disorders mediated by lymphocyte interactions, particularly diseases assocd. with EDG receptor mediated signal transduction. They were obsd. to exhibit selectivity for the EDG-1-receptor. For example, the compd. II had a EC50 of 0.6 nM in EDG-1(S1P1)GTP[g-35S] binding assay and was at least 1000 fold more selective for EDG-1 compared to one or more of the other receptors including EDF-3, EDG-5, EDG-6 and EDG-8. .